Novo Nordisk is spending $6 billion in Kalundborg, Denmark, to expand the production of active pharmaceutical ingredients (APIs), including peptides used in weight-loss and antidiabetic drugs. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results